Your browser doesn't support javascript.
loading
Glucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21.
Kim, Teayoun; Nason, Shelly; Holleman, Cassie; Pepin, Mark; Wilson, Landon; Berryhill, Taylor F; Wende, Adam R; Steele, Chad; Young, Martin E; Barnes, Stephen; Drucker, Daniel J; Finan, Brian; DiMarchi, Richard; Perez-Tilve, Diego; Tschöp, Matthias; Habegger, Kirk M.
Afiliação
  • Kim T; Comprehensive Diabetes Center and Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
  • Nason S; Comprehensive Diabetes Center and Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
  • Holleman C; Comprehensive Diabetes Center and Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
  • Pepin M; Division of Molecular and Cellular Pathology, Department of Pathology, University of Alabama at Birmingham, AL.
  • Wilson L; Department of Pharmacology, University of Alabama at Birmingham, Birmingham, AL.
  • Berryhill TF; Department of Pharmacology, University of Alabama at Birmingham, Birmingham, AL.
  • Wende AR; Division of Molecular and Cellular Pathology, Department of Pathology, University of Alabama at Birmingham, AL.
  • Steele C; Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
  • Young ME; Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
  • Barnes S; Department of Pharmacology, University of Alabama at Birmingham, Birmingham, AL.
  • Drucker DJ; Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, University of Toronto, Toronto, Ontario, Canada.
  • Finan B; Novo Nordisk Research Center Indianapolis, Indianapolis, IN.
  • DiMarchi R; Novo Nordisk Research Center Indianapolis, Indianapolis, IN.
  • Perez-Tilve D; Department of Chemistry, Indiana University, Bloomington, IN.
  • Tschöp M; Division of Endocrinology, Diabetes and Metabolism, Metabolic Diseases Institute, University of Cincinnati, Cincinnati, OH.
  • Habegger KM; Institute for Diabetes and Obesity, Helmholtz Zentrum München, München, Germany.
Diabetes ; 67(9): 1773-1782, 2018 09.
Article em En | MEDLINE | ID: mdl-29925501
ABSTRACT
Glucagon, an essential regulator of glucose and lipid metabolism, also promotes weight loss, in part through potentiation of fibroblast growth factor 21 (FGF21) secretion. However, FGF21 is only a partial mediator of metabolic actions ensuing from glucagon receptor (GCGR) activation, prompting us to search for additional pathways. Intriguingly, chronic GCGR agonism increases plasma bile acid levels. We hypothesized that GCGR agonism regulates energy metabolism, at least in part, through farnesoid X receptor (FXR). To test this hypothesis, we studied whole-body and liver-specific FXR-knockout (Fxr∆liver) mice. Chronic GCGR agonist (IUB288) administration in diet-induced obese (DIO) Gcgr, Fgf21, and Fxr whole-body or liver-specific knockout (∆liver) mice failed to reduce body weight when compared with wild-type (WT) mice. IUB288 increased energy expenditure and respiration in DIO WT mice, but not Fxr∆liver mice. GCGR agonism increased [14C]palmitate oxidation in hepatocytes isolated from WT mice in a dose-dependent manner, an effect blunted in hepatocytes from Fxr∆liver mice. Our data clearly demonstrate that control of whole-body energy expenditure by GCGR agonism requires intact FXR signaling in the liver. This heretofore-unappreciated aspect of glucagon biology has implications for the use of GCGR agonism in the therapy of metabolic disorders.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Glucagon / Receptores Citoplasmáticos e Nucleares / Fármacos Antiobesidade / Metabolismo Energético / Fatores de Crescimento de Fibroblastos / Fígado / Obesidade Tipo de estudo: Etiology_studies Limite: Animals Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Glucagon / Receptores Citoplasmáticos e Nucleares / Fármacos Antiobesidade / Metabolismo Energético / Fatores de Crescimento de Fibroblastos / Fígado / Obesidade Tipo de estudo: Etiology_studies Limite: Animals Idioma: En Ano de publicação: 2018 Tipo de documento: Article